Last reviewed · How we verify
group-B : Levofloxacin triple therapy
Levofloxacin triple therapy combines a fluoroquinolone antibiotic with two additional agents to inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
Levofloxacin triple therapy combines a fluoroquinolone antibiotic with two additional agents to inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Helicobacter pylori eradication in peptic ulcer disease, Resistant bacterial infections.
At a glance
| Generic name | group-B : Levofloxacin triple therapy |
|---|---|
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
| Drug class | Fluoroquinolone antibiotic combination therapy |
| Target | Bacterial DNA gyrase, topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Levofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair. The triple therapy formulation combines levofloxacin with additional antimicrobial agents (typically clarithromycin and amoxicillin or similar) to provide synergistic activity against resistant pathogens, particularly for eradication of Helicobacter pylori and other resistant infections.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease
- Resistant bacterial infections
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Headache
- Tendinopathy
- QT prolongation
Key clinical trials
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: